Amaryl

Chinese name: Amaryl pancreatic tablets

English name: Amaryl

Indications

Amaryl pancreatic tablets are a sulfonylurea drug that can be used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes.

Not suitable for the treatment of type 1 diabetes or diabetic ketoacidosis.

Dosage

The recommended starting dose is 1 or 2 mg once daily. Depending on glycemic response, increase by 1 or 2 mg no more frequently than every 1-2 weeks. The maximum recommended dose is 8 mg once daily.

Take with breakfast or first meal of the day.

Patients at increased risk of hypoglycemia (e.g., the elderly, patients with renal insufficiency) use a starting dose of 1 mg and titrate slowly.

Precautions

1. Hypoglycemia: It may be serious. Ensure proper patient selection, dosage, and instructions, especially in high-risk groups (e.g., elderly, renal insufficiency) and when used with other antidiabetic agents.

2. Hypersensitivity reactions: Post-marketing reports include allergic reactions, angioedema and Stevens-Johnson syndrome. If a reaction is suspected, discontinue MAR Pancreas immediately, evaluate other potential causes of the reaction, and institute alternative treatment for diabetes mellitus.

3. Hemolytic anemia: It may occur if glucose 6-phosphate dehydrogenase (G6PD) is deficient. Consider a non-sulfonylurea alternative.

4. Sulfonylureas may increase the risk of cardiovascular death: inform patients of the risks, benefits, and treatment options.

5. Macrovascular Outcomes: No clinical studies have established conclusive evidence of a reduction in macrovascular risk with the use of Malpancreas or any other antidiabetic drug.

Side Effects

Common adverse reactions in clinical trials (≥5%, more common than placebo) include hypoglycemia, headache, nausea, and dizziness.

Overdose Management

As with other sulfonylureas, overdose of Mal Pancreatic Lozenges can cause severe hypoglycemia. Mild hypoglycemic episodes can be treated with oral glucose. A severe hypoglycemic reaction constitutes a medical emergency requiring immediate treatment. Severe hypoglycemia associated with coma, seizures, or neurological deficits can be treated with glucagon or intravenous glucose. Continued observation and additional carbohydrate intake may be necessary because hypoglycemia may recur after apparent clinical recovery.